Xtant Medical Holdings, Inc. XTNT
0.38
0.00
0.00%
as of 25 Sep
- Market cap
- $52.9M
- P/E
- 0.0×
Follow XTNT
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
31.86 | 19.12 | 27.45 | 0.00 |
P/S ratio |
0.68 | 0.81 | 0.64 | 0.54 | |
P/FCF ratio |
16.56 | 10.47 | 9.81 | 0.00 | |
P/Operating CF |
19.69 | 20.23 | (37.10) | (8.06) | |
P/B ratio |
1.80 | 2.14 | 1.61 | 1.47 | |
Price to Tangible BV |
2.52 | 2.44 | 1.86 | 1.75 | |
EV/Sales |
0.82 | 0.87 | 0.64 | 0.65 | |
EV/EBITDA |
9.99 | 9.35 | 9.84 | 0.00 | |
EV/Operating CF |
13.91 | 9.32 | 8.58 | 125.76 | |
EV/FCF |
19.86 | 11.24 | 9.82 | (156.17) | |
Quick Ratio |
1.02 | 1.19 | 1.56 | 0.99 | |
Current Ratio |
2.21 | 2.65 | 3.34 | 2.16 | |
Net Debt/EBITDA |
4.89 | 9.22 | (0.04) | (1.47) | |
Debt/Assets |
27.03% | 26.97% | 15.72% | 28.86% | |
Debt/Equity |
0.57 | 0.50 | 0.25 | 0.57 | |
Asset Turnover |
1.30 | 1.42 | 1.40 | 1.20 | |
Operating CF/Net income |
3.53 | 94.39 | 0.68 | 0.78 | |
Capex/Depreciation |
(0.28) | (0.20) | (0.28) | (0.38) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.91% | 1.42% | 2.08% | 3.02% | |
Selling, General and Administrative Expense of Revenue |
56.58% | 56.37% | 69.23% | 72.96% | |
Intangible Assets out of Total Assets |
0.14 | 0.07 | 0.08 | 0.08 | |
Share Based Compensation of Revenue |
1.93% | 2.25% | 3.57% | 3.80% | |
Graham Net Nets |
0.25 | 0.32 | 0.42 | 0.43 | |
Graham Number |
0.41 | 0.58 | 0.40 | 0.00 | |
Earnings Yield |
3.14% | 5.23% | 3.64% | (18.95%) | |
Free Cash Flow Yield |
6.04% | 9.55% | 10.20% | (0.78%) | |
Revenue per Share |
0.24 | 0.23 | 0.15 | 0.16 | |
Operating CF per Share |
0.03 | 0.04 | (0.02) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | 0.04 | (0.02) | (0.05) | |
Cash per Share |
0.08 | 0.12 | 0.09 | 0.07 | |
Shareholders Equity per Share |
0.36 | 0.37 | 0.35 | 0.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 0.37 | 0.35 | 0.29 | |
Free Cash Flow |
4.29 | 5.01 | (2.26) | (7.50) | |
Working Capital |
42.83 | 48.76 | 43.85 | 34.81 | |
Capital Expenditures |
(0.32) | (0.37) | (0.15) | (0.19) | |
Net Current Asset Value |
22.39 | 35.05 | 33.22 | 25.13 | |
EV/EBIT |
17.16 | 16.05 | 23.81 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
3.93% | 0.18% | (14.79%) | (40.87%) | |
Price to Operating Income |
14.31 | 14.94 | 23.78 | 0.00 | |
| Other line items | |||||
Average Receivables |
23.03 | 19.23 | 20.33 | 23.18 | |
Average Payables |
7.58 | 5.88 | 6.30 | 6.69 | |
Average Inventory |
41.30 | 34.45 | 35.35 | 36.71 | |
Average Assets |
102.60 | 93.99 | 86.92 | 91.57 | |
Average Common Equity |
48.05 | 46.96 | 46.24 | 44.26 |
Columns are period end dates